The Abbott Vascular Devices (Redwood City, California) division of Abbott Laboratories (Abbott Park, Illinois) reported in mid-September that it had enrolled the first patient in its ZOMAXX I drug-eluting coronary stent clinical trial. ZOMAXX I is a 400-patient, randomized clinical trial that will be conducted in more than 30 centers in Europe, Australia and New Zealand.